The content on this site is intended for healthcare professionals only
Global horizons of the WIN consortium
What is the WIN Consortium?
Pembrolizumab and indoximod for melanoma
Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030
Nivolumab for NSCLC: five years on
Avelumab for metastatic Merkel cell carcinoma after chemotherapy
Nivolumab and ipilimumab combination for advanced skin cancer
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Checkmate 067 - combined nivolumab and ipilimumab
Glycemia positively associated with prostate cancer mortality in non-diabetic men
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Durable responses to avelumab in patients with Merkel cell carcinoma
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses
Five-year follow-up of nivolumab in NSCLC
Mutations in cancer predisposition genes and risk for subsequent neoplasms
Final overall survival analysis of MONARCH 1
Redefining tamoxifen for breast cancer
Olaparib and temozolomide for relapsed small cell lung cancer
Treatment choices for HER2 amplified colorectal cancer
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours
Neratinib in HER2 or HER3 mutant solid tumours
Understanding response and resistance to cancer therapy: Lessons learned from melanoma
Tumour-treating fields complement chemotherapy in aggressive brain tumours
Tumour treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM):
